Relmada Therapeutics, Inc.
NASDAQRelmada Therapeutics enters June on the back foot, down 16% in a month after a sharp re-rating higher — and fresh dilution news is the clearest explanation for why the momentum has stalled. The most consequential recent development is structural rather than clinical. On May 27, shareholders approved an increase in authorized common stock from 150 million to 200 million shares. That…
RLMD cost to borrow surges to 1.40%, up 178% in one week—sharpest spike in months as borrowed shares tighten amid biotech momentum.
Snapshot as of 3 Jun 2026
Relmada Therapeutics enters June on the back foot, down 16% in a month after a sharp re-rating higher — and fresh dilution news is the clearest explanation for why the momentum has stalled. The most consequential…
RLMD dropped its Q1 results on May 12 and filed a mixed-shelf offering the same evening — two developments that together define the stock's near-term tension: a credible clinical story advancing toward a mid-2026 Phase…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RLMD — free to start on ORTEX.
Sign up for free →Open RLMD on ORTEX